Literature DB >> 11476966

Prolonged Jun N-terminal kinase (JNK) activation and the upregulation of p53 and p21(WAF1/CIP1) preceded apoptosis in hepatocytes after partial hepatectomy and cisplatin.

K Kobayashi1, I Tsukamoto.   

Abstract

Cisplatin induced apoptosis in regenerating liver after partial hepatectomy (PH). Apoptosis was determined by in situ end-labeling and gel electrophoresis of DNA fragmentation. Characteristic DNA fragmentation was obvious at 4 h and peaked at 8 h after PH. The activity of Jun N-terminal kinase (JNK) transiently increased at 1 h after PH. However, in cisplatin-injected rats, the JNK activity increased at 30 min and the increased level was maintained up to 4 h after PH. The in vivo activation of JNK was confirmed by the increased level of the phosphorylated c-Jun protein. Western blot analysis showed that the phosphorylated c-Jun level increased at 1 h and reached more than 30-fold the control level at 2 h after PH with cisplatin. The c-jun mRNA levels also markedly increased at 1 h after PH with cisplatin. The protein level of p53 increased after 1 h on cisplatin injection, but no significant change in the mRNA level was observed. The rise in the p53 protein level was followed by the upregulation of p21(WAF1/CIP1) mRNA and protein levels. These results suggested that the enhanced and sustained JNK activation and the upregulation of p53 and p21(WAF1/CIP1) were involved in hepatocyte apoptosis induced by PH with cisplatin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11476966     DOI: 10.1016/s0925-4439(01)00059-x

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Epidermal growth factor differentially augments G(i)-mediated stimulation of c-Jun N-terminal kinase activity.

Authors:  Anthony S L Chan; Yung H Wong
Journal:  Br J Pharmacol       Date:  2004-06-01       Impact factor: 8.739

2.  Protective agent, erdosteine, against cisplatin-induced hepatic oxidant injury in rats.

Authors:  Ahmet Koc; Mehmet Duru; Harun Ciralik; Ramazan Akcan; Sadik Sogut
Journal:  Mol Cell Biochem       Date:  2005-10       Impact factor: 3.396

3.  Inhibition of NF-kappaB activation by the histone deacetylase inhibitor 4-Me2N-BAVAH induces an early G1 cell cycle arrest in primary hepatocytes.

Authors:  P Papeleu; A Wullaert; G Elaut; T Henkens; M Vinken; G Laus; D Tourwé; R Beyaert; V Rogiers; T Vanhaecke
Journal:  Cell Prolif       Date:  2007-10       Impact factor: 6.831

4.  Molecular mechanisms of hepatocellular apoptosis induced by trovafloxacin-tumor necrosis factor-alpha interaction.

Authors:  Kevin M Beggs; Aaron M Fullerton; Kazuhisa Miyakawa; Patricia E Ganey; Robert A Roth
Journal:  Toxicol Sci       Date:  2013-10-04       Impact factor: 4.849

5.  c-Jun/AP-1 controls liver regeneration by repressing p53/p21 and p38 MAPK activity.

Authors:  Ewa Stepniak; Romeo Ricci; Robert Eferl; Grzegorz Sumara; Izabela Sumara; Martina Rath; Lijian Hui; Erwin F Wagner
Journal:  Genes Dev       Date:  2006-08-15       Impact factor: 11.361

6.  p53 Contributes to Differentiating Gene Expression Following Exposure to Acetaminophen and Its Less Hepatotoxic Regioisomer Both In Vitro and In Vivo.

Authors:  Brendan D Stamper; Michael L Garcia; Duy Q Nguyen; Richard P Beyer; Theo K Bammler; Frederico M Farin; Terrance J Kavanagh; Sidney D Nelson
Journal:  Gene Regul Syst Bio       Date:  2015-06-01

7.  Gallic Acid Induces a Reactive Oxygen Species-Provoked c-Jun NH2-Terminal Kinase-Dependent Apoptosis in Lung Fibroblasts.

Authors:  Chiu-Yuan Chen; Kun-Chieh Chen; Tsung-Ying Yang; Hsiang-Chun Liu; Shih-Lan Hsu
Journal:  Evid Based Complement Alternat Med       Date:  2013-02-20       Impact factor: 2.629

8.  VRK1 promotes cisplatin resistance by up-regulating c-MYC via c-Jun activation and serves as a therapeutic target in esophageal squamous cell carcinoma.

Authors:  Zhen-Chuan Liu; Kuo Cao; Zhao-Hua Xiao; Liang Qiao; Xue-Qing Wang; Bin Shang; Yang Jia; Zhou Wang
Journal:  Oncotarget       Date:  2017-08-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.